Welcome to our dedicated page for Beta Bionics news (Ticker: BBNX), a resource for investors and traders seeking the latest updates and insights on Beta Bionics stock.
Beta Bionics reports developments for a commercial-stage medical device company focused on diabetes management for insulin-requiring people. Its core product, the iLet Bionic Pancreas, uses adaptive closed-loop algorithms and is an FDA-cleared insulin delivery device that autonomously determines insulin doses.
Company news commonly covers quarterly financial results and guidance, net sales through Durable Medical Equipment and Pharmacy Benefit Plan channels, new patient starts, product software such as Bionic Insights within Bionic Reports, and diabetes-technology development programs including the Mint patch pump and bihormonal system.
Beta Bionics (Nasdaq: BBNX) updated expectations for Mint, its ACE insulin patch pump in development. The company now anticipates full commercialization by the end of Q2 2027, subject to FDA 510(k) clearance, and reports progress scaling manufacturing to meet anticipated launch demand.
Planned features include compatibility with Beta Bionics’ FDA-approved iAGC algorithm, leading CGMs, smartphone control, three-day wear, 200-unit reservoir, waterproofing, pharmacy-only availability, and a reusable/disposable design to limit environmental waste.
Beta Bionics (Nasdaq: BBNX) will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 PM ET (11:20 AM PT).
A live audio webcast will be available on the company’s Investors & Events page at https://investors.betabionics.com and will be archived there for future replay.
Beta Bionics (Nasdaq: BBNX) reported Q1 2026 results and raised full-year 2026 guidance. Net sales $27.6M (+57% YoY); gross margin 59.5% (up 864 bps YoY). Cash and investments $239.5M as of March 31, 2026.
Company raised 2026 revenue guidance to $131M–$136M and updated gross margin guidance to 57.5%–59.5%; PBP channel mix forecast increased to 37%–39% of new patient starts.
Beta Bionics (NASDAQ:BBNX) on March 31, 2026 launched Bionic Insights™, a new feature inside Bionic Reports that organizes patient data into Areas of Success and Areas of Opportunity to help clinicians make personalized, actionable treatment recommendations for people using the iLet Bionic Pancreas.
The feature surfaces clinically relevant indicators, patient activities, and system events to reduce time spent interpreting raw data and support focused provider–patient conversations.
Beta Bionics (Nasdaq: BBNX) will release its first quarter 2026 financial results after markets close on April 21, 2026. Management will host a conference call and concurrent webcast the same day at 4:30 PM ET (1:30 PM PT) to review Q1 2026 performance.
The live webcast link and archived replay will be available in the Investors & Events section at the company website, and phone access requires registration for dial-in details and a personal PIN.
Beta Bionics (Nasdaq: BBNX) announced management will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am ET. A live audio webcast will be available on the company’s investor site and archived for later replay.
Beta Bionics (Nasdaq: BBNX) reported strong 2025 growth with $100.3M revenue (+54% YoY) and Q4 net sales of $32.1M (+57% YoY). Installed base reached 35,011 users (+129% YoY) and cash/investments were $264.7M at year-end. The company completed a first-in-human Phase 2a bihormonal feasibility trial and provided 2026 guidance of $130M–$135M revenue, 36%–38% PBP reimbursement, and 55.5%–57.5% gross margin.
Beta Bionics (Nasdaq: BBNX) reported preliminary, unaudited topline results for Q4 2025, with net sales of at least $32.0 million (up at least 56% vs. $20.4M in Q4 2024). DME channel sales expected at least $22.3 million (up at least 23% YoY) and PBP channel sales expected at least $9.7 million (up at least 308% YoY).
The installed customer base is expected to be at least 35,000 users (up at least 128% YoY). New patient starts are expected to be at least 5,581 (up at least 36% YoY), with ~69% converting from MDI, ~25–30% with type 2 diabetes, and a low-30s% share reimbursed through PBP. Fourth quarter and full year 2025 results will be released Feb 17, 2026 with a conference call at 4:30 PM ET.
Beta Bionics (Nasdaq: BBNX) plans to pre-release topline fourth quarter 2025 financial results in the week of January 5, 2026. The pre-release is expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP). Company management will hold in-person investor meetings in San Francisco from January 12–14, 2026 to discuss the topline results. Investors may register for meetings by contacting investor relations at ir@betabionics.com.
Beta Bionics (Nasdaq: BBNX) announced management will present at two upcoming investor conferences in November and December 2025. Presentations are scheduled for Wolfe Research 7th Annual Healthcare Conference on November 18, 2025 at 2:00 PM ET and Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 4:30 PM ET. Both sessions will be webcast live and archived for replay. Webcast links will be posted in the company’s Investors & Events section at https://investors.betabionics.com.